ArticleDiscover oncology2025
PCED1A serves as a potential biomarker for diagnosis and prognosis in colorectal cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundThe heterogeneity of colorectal cancer (CRC) necessitates a comprehensive understanding of its pathogenesis and the identification of potential therapeutic targets. This research aims to report on PCED1A, a gene that has not been reported in any cancer, and to focus on investigating its role in CRC.
methodsIn the present study, the CRC expression profiles and associated clinical data from the TCGA database were utilized as the test set, complemented by three GEO datasets serving as the validation cohort. A thorough examination of PC-esterase domain-containing protein 1 A (PCED1A) was undertaken, including differential expression, ROC analysis, clinical correlation, survival analysis, subgroup analysis, co-expression, pathway enrichment, immune infiltration, and the development of a clinical prediction model. Finally, expression validation was also conducted through immunohistochemistry.
resultsDifferential expression analysis revealed that PCED1A is abnormally highly expressed in CRC and shows consistency across various cancer types. ROC analysis suggested that the gene possesses good diagnostic efficacy. The survival analysis showed that elevated PCED1A expression is strongly linked to a poor prognosis. The clinical prediction model, constructed from PCED1A and various clinical factors, could also more accurately predict the survival outcomes of CRC patients. Furthermore, the association of PCED1A expression with clinical-pathological features such as cancer subtype, race, and advanced clinical stages indicates its potential role in the molecular heterogeneity of CRC. The enrichment analysis suggested that the oncogenic mechanism of PCED1A might involve the modulation of the Notch and Wnt signaling pathways to impact tumor immune response. Finally, the abnormal high expression of PCED1A in CRC was validated by three GEO datasets and CRC cancer tissue specimens.
conclusionThis investigation observes an abnormally high expression of PCED1A in CRC. The gene not only shows promise in CRC for both diagnostic and prognostic purposes but also displays robust correlations with clinical-pathological characteristics. PCED1A has the potential to become a new biomarker for precision individualized treatment in CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.